calcium acetate (Phoslo)

08/28/2020 - "He was also started on calcium acetate 1,334 mg three times a day for hyperphosphatemia. "
07/01/2005 - "One of the top 2 common clinical treatments for hyperphosphatemia, calcium acetate, has an established history of efficacy since the 1980s, and has been shown to be cost effective and well tolerated, as well."
08/01/2002 - "A new gelcap form of calcium acetate has been introduced for control of hyperphosphatemia. "
11/01/2008 - "Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study."
01/01/1993 - "All patients received calcium acetate or calcium carbonate to control hyperphosphatemia during the study. "

09/01/2015 - "Hypercalcemia occurred in 4 participants receiving calcium acetate. "
05/01/2004 - "By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). "
02/16/2011 - "At 12 weeks, the proportions of subjects who had hypocalcemia were 5.4% and 19.5% for the calcium acetate and the placebo groups, respectively, while the proportions of those with hypercalcemia were 13.5% and 0%, respectively. "
01/01/2017 - "Although one meta-analysis suggested that calcium acetate may be more efficacious gram for gram than calcium carbonate as a binder, calcium acetate did not reduce hypercalcemia, and gastrointestinal intolerance was higher. "
05/01/2004 - "Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. "

09/01/2002 - "The metabolic and skeletal effects of a possible remedy, calcium acetate, have not been studied in patients with preterminal chronic renal failure. "
09/01/2002 - "Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure."
01/01/2019 - "The results of the study do not suggest increased cardiovascular safety of sevelamer in the routine clinical practice of patients with ESRD compared with calcium acetate; this study's findings suggest that well-designed, long-term, randomized clinical trials are needed."
01/01/2011 - "A total of 52 patients with ESRD on maintenance haemodialysis were screened for enrolment; 26 patients were randomized to each of the sevelamer and calcium acetate groups. "
01/01/2019 - "Participants included patients 65 years or older with ESRD within 180 days after starting hemodialysis (sevelamer, 2647; calcium acetate, 2074). "

12/01/2010 - "Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4."
02/16/2011 - "A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease."
08/01/2009 - "This study was, therefore, undertaken to compare the efficacy and tolerability of lanthanum carbonate with calcium acetate in patients with stage 4 chronic kidney disease. "
08/01/2009 - "Following Institutional Ethics Committee approval and valid consent, patients with stage 4 chronic kidney disease were randomized to receive either lanthanum carbonate 500mg thrice daily or calcium acetate 667 mg thrice daily for 4 weeks. "
08/01/2009 - "Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease."

01/01/2020 - "Despite strict dietary constraints and compliance, phosphate binders such as calcium acetate and/or sevelamer carbonate are also needed to treat secondary hyperparathyroidism. "
07/01/2009 - "Only 130 patients received secondary hyperparathyroidism treatment within 5 years after transplantation: calcium carbonate, 36.9%; calcium acetate, 1.5%; calcium carbonate plus cholecalciferol, 21%; calcitriol, 71%; and calcifediol, 0.8%. "
08/01/1995 - "In this study, we prospectively evaluated the efficacy of calcium acetate in patients with chronic renal insufficiency on hemodialysis programme with secondary hyperparathyroidism and hyperphosphatemia, which are difficult to control by means of the usual finders (calcium carbonate and aluminium hydroxide) and who were treated with pulses of calcitriol. "